Peekskill Fire Department

Local news you care about.

Creating Awareness Through Oncortarget In a Bid To Fight Cancer

Based in the United States of America, Oncortarget is a peer-reviewed open access medical journal that talks about oncology. Oncology is simply a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. Its research is mainly on cancerous tumors, how to manage them and treat them if possible especially during the early stages. Oncology basically encompasses three components of dealing with cancer. One is prevention where a person is strictly advised to avoid the causative agents of cancer like tobacco. The second phase involves an early diagnosis of the abnormal growth. This includes screening of common cancers and intensive diagnosis and staging. The last phase is the treatment of the disease. Here the tumor board carries out a lot of discussions about the abnormal growth and how to deal with it. Treatment might also be offered if possible by a comprehensive cancer treatment center.

Oncortarget itself is a term that encompasses molecules, particles cellular functions common in aging and cancer. Furthermore, it also entails neurodegeneration, lymphocytes, neurons, cancer cells, and microbes. The oncortarget journal is published on a weekly basis by Impact Journals. Formed in 2010, Oncortarget is led by a team of experts highly skilled in the various roles they play. Mikhail Blagosklonny and Andrei V. Gudkov are some of the top-notch employees at Oncortarget. In fact, the two are the editors in chief of Oncortarget journal which is usually published in English. Mikhail Blagosklonny for one, is a man with great experience and expertise in the field of oncology. He holds an M.D in internal medicine and a Ph.D. in experimental medicine and cardiology from the First Pavlov State University of St. Petersberg, He is a scientist who constantly studies cancer and aging. Formerly, Mikhail Blagosklomy was a professor of oncology at the Roswell Park Cancer Institute.

Oncortarget is devoted to making scientific results widely available and within the shortest time possible. It also aims at doing away with borders between specialties and link different sectors of medical research together as one. Furthermore, Oncortarget allows different researchers from diverse biomedical fields to share their different findings and discoveries.With its ultimate goal, “Life Without Diseases,” in mind, Oncortarget hopes that the journal will constantly help researchers contribute to science and eradicate diseases. Endowed with the great scientists and medical experts, Oncortarget is slowly growing and covering other fields of health. In fact, having had massive success in the previous years, the journal has begun launching sections beyond oncology. Neuroscience, Cardiology, Cell Biology, Metabolism, and Endocrinology are some examples of these sections. Not to forget, Pharmacology, where Oncortarget covers all areas in this particular section.

Dr. Reddy Recommends MB2 Dental

Dr. Reddy Akhil is a dental practitioner at MB2 Dental. He is one of the renowned dentists in America with a clientele that comes from a wide radius. Dr. Akhil was born and raised in Texas, where he readily interacted with people from all walks of life. As a child, Dr. Akhil showed interests in soccer, which he played with other kids in school. He also showed interest in humanitarian activities by joining clubs such as Red Cross and Scouting. The above is now interpreted as the desire to serve humanity, which Dr. Akhil does to date.Dr. Akhil was a very creative student, who knew from an early age that he needed to pursue a career path that allowed him to use his creativity. Specifically, he wanted to pursue either dentistry or engineering courses, but he eventually settled for the dentistry course. He went to the University Of The Pacific, where he pursued a Bachelor of Science in Biology and his masters in dentistry. At the age of 23, he acquired his doctorate of dental surgery from the university.

Upon completing his studies, Dr. Akhil went back to Texas to pursue his career. Some of the problems experienced at this time were how to raise capital or to purchase a venture. However, he managed to buy a practice and run it for a while. However, he experienced staffing and administration problems since he had to manage his little time doing all the administration and attending to the patients. Moreover, he had no way of acquiring supplies cheaply since he bought them in small scale. Eventually, the venture failed to be profitable, forcing him to sell it at a loss.It was at this juncture that Dr. Akhil met Dr. Chris Villanuella, the founder of MB2 Dental and partnered with him.

MB2 Dental is a venture that merges the private and corporate dental practices to make them more viable. Dr. Chris understands the challenges of having a private practice and at the same time those of the cooperate setting. The former configuration burdens the practitioner with too many activities that rob him of the time he needs to attend to patients. It is also costly for the practitioner. On the other hand, the latter makes the dentist an object of exploitation as profits are the primary motives of the corporate owners. In both the above cases, the patients also receive little or no attention. MB2 Dental sorts the issue by making the dentist the center of attention.Dr. Aphil is a humble man who values and listens to his staff. Moreover, he treats patients even when they come from low-income backgrounds as money is not his drive.

Mikhail Blagosklonny Develops Oncotarget for Cancer Research and Treatment

With it comes an emotional, financial and physical challenge for both the infected and affected. It takes more than just a family to fight the disease. Currently, approximately 6.7 million people lose their lives to cancer every year. That is why scientists and physicians have heavily invested in cancer research centers and journals with the objective of finding treatment. Cancer Treatment involves growth regulation in the body cells. A good example of such journals is the Oncotarget.

Oncotarget

Oncotarget is a weekly medical journal on research covering all scopes of oncology. After its establishment in 2010, Impact Journals took the role of publishing it. The chief editors of the journal are prominent scientists; Mikhail Blagosklonny, an oncologist and lead researcher at Roswell Research Center for Cancer and Andrei V. Gudkov. The journal plays a vital role in the dissemination of cancer-related information to the community. With its weekly publications, most people can be reached.

Research

Individuals are adopting modern research methods and ideas to treat diseases. With Oncotarget being a top scientific journal, most physicians embark on it for research. Families and patients refer to Oncotarget for educative reasons. Oncotarget has made remarkable gains discernible by educative articles on the symptoms and treatment of cancer.

E-Cigarettes

Recently, an innovative research by Oncotarget showed that e-cigarettes have adverse effects on smoker’s gums. Additionally, Oncotarget has published new research on cervical cancer and drugs being the causative agents for weight loss in cancer patients. Oncotarget further explains the possibilities of a strong modern element that can be utilized in the treatment of cancer. The new researchers play an essential role in tackling cancer. They also offer an innovative platform for the research and treatment of e-cigarette. Most researchers illuminate the possibility of misconception in conformism. Oncotarget is also available on Dove Press.

Mikhail Blagosklonny

Mikhail Blagosklonny serves as the chief editor of Oncotarget, a multidisciplinary conventional journal freely accessible. Under his leadership, Oncotarget publishes articles online with the aim of educating the community on cancer awareness, research, and treatment. Each article is readily available for printing upon demand. Follow Oncotarget journal on Twitter.